A partir de données portant sur 592 patients atteints d'un endobrachyœsophage traité par mucosectomie endoscopique et/ou par ablation par radiofréquence, cette étude évalue les risques de récidive et identifie les facteurs associés

Recurrence of Esophageal Intestinal Metaplasia After Endoscopic Mucosal Resection and Radiofrequency Ablation of Barrett's Esophagus: Results From a US Multicenter Consortium

Gupta, Milli ; Iyer, Prasad G. ; Lutzke, Lori ; Gorospe, Emmanuel C. ; Abrams, Julian A. ; Falk, Gary W. ; Ginsberg, Gregory G. ; Rustgi, Anil K. ; Lightdale, Charles J. ; Wang, Timothy C. ; Fudman, David I. ; Poneros, John M. ; Wang, Kenneth K.

Radiofrequency ablation (RFA) is an established treatment for dysplastic Barrett’s esophagus (BE). Although short-term endpoints of ablation have been ascertained, there have been concerns about recurrence of intestinal metaplasia (IM) after ablation. We aimed to estimate the incidence and identify factors that predicted the recurrence of IM after successful RFA. We analyzed data from 592 patients with BE treated with RFA from 2003 through 2011 at 3 tertiary referral centers. Complete remission [...]

Menée sur une cohorte de 163 patients atteints d'un cancer du pénis traité entre 2003 et 2012, cette étude évalue le taux de complications précoces après une lymphadénectomie inguinale et analyse les facteurs de risque associés

Early Wound Complications After Inguinal Lymphadenectomy in Penile Cancer: A Historical Cohort Study and Risk-factor Analysis

Martijn, M. Stuiver ; Rosa, S. Djajadiningrat ; Niels, M. Graafland ; Andrew, D. Vincent ; Cees, Lucas ; Simon, Horenblas

Background : Complication rates after inguinal lymph node dissection (ILND) are high. Risk factors for early wound complications after ILND in patients with penile carcinoma have not yet been studied. Objectives : To assess the frequency of early wound complications in a contemporary series and to identify clinical risk factors for early wound complications after ILND for penile carcinoma. Design, setting, and participants : We evaluated 237 ILNDs in 163 patients with penile cancer treated [...]

Menée sur une cohorte de 6 489 hommes atteints d'un cancer localisé de la prostate traité entre 1995 et 2011 (durée médiane de suivi : 4 ans), cette étude observationelle danoise évalue, en fonction du stade de la maladie avant traitement, du niveau sérique de l'antigène prostatique spécifique et du score de Gleason, la survie des patients après une prostatectomie radicale

Survival after radical prostatectomy for clinically localised prostate cancer: a population-based study

Røder, Martin Andreas ; Brasso, Klaus ; Christensen, Ib Jarle ; Johansen, Jørgen ; Langkilde, Niels Christian ; Hvarness, Helle ; Carlsson, Steen ; Jakobsen, Henrik ; Borre, Michael ; Iversen, Peter

Objectives : To describe survival and cause of death in a nationwide cohort of Danish patients with prostate cancer undergoing radical prostatectomy (RP). * To describe risk factors associated with prostate cancer mortality. Patients and Methods * Observational study of 6489 men with localised prostate cancer treated with RP at six different hospitals in Denmark between 1995 and 2011. * Survival was described using Kaplan–Meier estimates. Causes of death were obtained from the national registry [...]

Cet article passe en revue les études récentes concernant l'efficacité, la toxicité et le coût de la protonthérapie pour traiter un cancer localisé de la prostate, puis analyse les controverses associées

Proton beam therapy and localised prostate cancer: current status and controversies

Efstathiou, J. A. ; Gray, P. J. ; Zietman, A. L.

Proton therapy is a promising, but costly, treatment for prostate cancer. Theoretical physical advantages exist; yet to date, it has been shown only to be comparably safe and effective when compared with the alternatives and not necessarily superior. If clinically meaningful benefits do exist for patients, more rigorous study will be needed to detect them and society will require this to justify the investment of time and money. New technical advances in proton beam delivery coupled with [...]

Menée à partir de données administratives portant sur 10 596 patients atteints d'un carcinome non métastatique à cellules rénales et ayant subi une néphrectomie, cette étude montre qu'une lymphadénectomie étendue n'améliore pas la survie des patients présentant des métastases ganglionnaires

Extent of lymphadenectomy does not improve the survival of patients with renal cell carcinoma and nodal metastases: biases associated with the handling of missing data

Sun, Maxine ; Trinh, Quoc-Dien ; Bianchi, Marco ; Hansen, Jens ; Abdollah, Firas ; Tian, Zhe ; Shariat, Shahrokh F. ; Montorsi, Francesco ; Perrotte, Paul ; Karakiewicz, Pierre I.

What's known on the subject? and What does the study add? * A recent population-based analysis suggested a potential survival benefit with respect to performing lymph node dissection at nephrectomy in node-positive patients with RCC. * The findings of the present study failed to corroborate the association of a survival benefit with the performance of lymph node dissection at nephrectomy. Objective * Previous studies showed no survival benefit with respect to performing lymph node dissection [...]

A partir d'une revue systématique de la littérature publiée entre 2000 et 2012 (6 études, 256 patients), cette méta-analyse compare, du point de vue de données péri-opératoires et du taux de complications, deux techniques de néphrectomie partielle, l'une réalisée par laparoscopie et l'autre assistée par robot, pour traiter des tumeurs rénales de stade T1a

Evaluation of robotic and laparoscopic partial nephrectomy for small renal tumours (T1a)

Froghi, Saied ; Ahmed, Kamran ; Khan, Mohammad S. ; Dasgupta, Prokar ; Challacombe, Ben

Objective : To compare laparoscopic partial nephrectomy (LPN) with robotic PN (RPN) using meta-analytical techniques, since there has been a rise in the incidence of small renal masses (SRM; <4 cm) minimally invasive approaches are becoming more popular in dealing with such pathologies. Materials and Methods * A systematic review of the literature was performed to identify studies comparing LPN and RPN. * Comparative studies evaluating RPN and LPN that fulfilled the inclusion criteria were [...]

Menée sur 10 patients pédiatriques atteints d'une tumeur tératoïde rhabdoïde atypique du système nerveux central et traités entre 2004 et 2011 (âge médian : 2,3 ans ; durée médiane de suivi : 27,3 mois), cette étude analyse les premiers résultats cliniques associés à une protonthérapie

Early Clinical Outcomes Using Proton Radiation for Children With Central Nervous System Atypical Teratoid Rhabdoid Tumors

De Amorim Bernstein, Karen ; Sethi, Roshan ; Trofimov, Alexei ; Zeng, Chuan ; Fullerton, Barbara ; Yeap, Beow Y. ; Ebb, David ; Tarbell, Nancy J. ; Yock, Torunn I. ; MacDonald, Shannon M.

Atypical teratoid/rhabdoid tumor (AT/RT) is an uncommon and aggressive tumor that often affects infants. Irradiation improves survival but has traditionally been avoided in patients under the age of 3 due to the increasing risk of neurocognitive side effects. We report the first cohort of AT/RT patients treated with proton therapy. All patients with AT/RT treated at Massachusetts General Hospital (MGH) Frances H. Burr Proton Beam Therapy Benter between July 2004 and November 2011 were included [...]

Menée à l'aide d'un modèle murin, cette étude évalue l'intérêt d'un traitement à base d'acide alpha lipoïque ou d'un composé appelé HC-030031 pour prévenir une neuropathie périphérique induite par une chimiothérapie à base de bortezomib ou d'oxaliplatine

Novel therapeutic strategy to prevent chemotherapy-induced persistent sensory neuropathy by TRPA1 blockade

Trevisan, Gabriela ; Materazzi, Serena ; Fusi, Camilla ; Altomare, Alessandra ; Aldini, Giancarlo ; Lodovici, Maura ; Patacchini, Riccardo ; Geppetti, Pierangelo ; Nassini, Romina

Chemotherapy-induced peripheral neuropathy (CIPN) is a severe and painful adverse reaction of cancer treatment in patients that is little understood or treated. Cytotoxic drugs that cause CIPN exert their effects by increasing oxidative stress, which activates the ion channel TRPA1 expressed by nociceptors. In this study, we evaluated whether TRPA1 acted as a critical mediator of CIPN by bortezomib or oxaliplatin in a mouse model system. Bortezomib evoked a prolonged mechanical, cold, and [...]

Menée in vitro et à l'aide d'un modèle murin, cette étude évalue les mécanismes d'action d'un anticorps monoclonal ciblant la protéine produite par l’oncogène WT1

Targeting the Intracellular WT1 Oncogene Product with a Therapeutic Human Antibody

Dao, Tao ; Yan, Su ; Veomett, Nicholas ; Pankov, Dmitry ; Zhou, Liang ; Korontsvit, Tatyana ; Scott, Andrew ; Whitten, Joseph ; Maslak, Peter ; Casey, Emily ; Tan, Taochao ; Liu, Hong ; Zakhaleva, Victoria ; Curcio, Michael ; Doubrovina, Ekaterina ; O’Reilly, Richard J. ; Liu, Cheng ; Scheinberg, David A.

The Wilms tumor 1 (WT1) oncoprotein is an intracellular, oncogenic transcription factor that is overexpressed in a wide range of leukemias and solid cancers. RMFPNAPYL (RMF), a WT1-derived CD8+ T cell human leukocyte antigen (HLA)–A0201 epitope, is a validated target for T cell–based immunotherapy. Using phage display technology, we discovered a fully human “T cell receptor–like” monoclonal antibody (mAb), ESK1, specific for the WT1 RMF peptide/HLA-A0201 complex. ESK1 bound to several leukemia [...]

Menée in vitro et in vivo sur des modèles de lymphomes de Burkitt surexprimant le gène c-Myc, cette étude analyse les mécanismes d'action d'un composé appelé ST1326, un inhibiteur d'une enzyme du métabolisme, CPT1A

Carnitine-Acyltransferase System Inhibition, Cancer Cell Death, and Prevention of Myc-Induced Lymphomagenesis

Pacilli, Annalisa ; Calienni, Maria ; Margarucci, Sabrina ; D’Apolito, Maria ; Petillo, Orsolina ; Rocchi, Laura ; Pasquinelli, Gianandrea ; Nicolai, Raffaella ; Koverech, Aleardo ; Calvani, Menotti ; Peluso, Gianfranco ; Montanaro, Lorenzo

Background The metabolic alterations of cancer cells represent an opportunity for developing selective antineoplastic treatments. We investigated the therapeutic potential of ST1326, an inhibitor of carnitine-palmitoyl transferase 1A (CPT1A), the rate-limiting enzyme for fatty acid (FA) import into mitochondria. Methods ST1326 was tested on in vitro and in vivo models of Burkitt’s lymphoma, in which c-myc, which drives cellular demand for FA metabolism, is highly overexpressed. We performed [...]

Menée sur des lignées cellulaires de cancer du poumon non à petites cellules et à l'aide de xénogreffes, cette étude évalue les mécanismes d'action d'un composé appelé NVP-AUY922, un inhibiteur de la protéine de choc thermique HSP90

The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth

Garon, Edward B ; Finn, Richard S. ; Hamidi, Habib ; Dering, Judy ; Pitts, Sharon ; Kamranpour, Naeimeh ; Desai, Amrita J ; Hosmer, Wylie ; Ide, Susan ; Avsar, Emin ; Rugaard Jensen, Michael ; Quadt, Cornelia ; Liu, Manway ; Dubinett, Steven M. ; Slamon, Dennis J

Heat shock protein 90 (HSP90) is involved in protein folding and functions as a chaperone for numerous client proteins, many of which are important in non-small cell lung cancer (NSCLC) pathogenesis. We sought to define preclinical effects of the HSP90 inhibitor NVP-AUY922 and identify predictors of response. We assessed in vitro effects of NVP-AUY922 on proliferation and protein expression in NSCLC cell lines. We evaluated gene expression changes induced by NVP-AUY922 exposure. Xenograft [...]

Menée à l'aide de modèles murins de cancer du poumon, cette étude met en évidence des mécanismes par lesquels, en modulant l'activation des macrophages intratumoraux, un composé appelé DMXAA augmente l'efficacité d'une immunothérapie

Using macrophage activation to augment immunotherapy of established tumours

Fridlender, Z. G. ; Jassar, A. ; Mishalian, I. ; Wang, L. Cs ; Kapoor, V. ; Cheng, G. ; Sun, J. ; Singhal, S. ; Levy, L. ; Albelda, S. M.

Background: Successful immunotherapy will require alteration of the tumour microenvironment and/or decreased immune suppression. Tumour-associated macrophages (TAMs) are one major factor affecting tumour microenvironment. We hypothesised that altering TAM phenotype would augment the efficacy of immunotherapy. Methods: We and others have reported that 5,6-Dimethylxanthenone-4-acetic-acid (DMXAA, Vadimezan) has the ability to change TAM phenotypes, inducing a tumour microenvironment conducive to [...]

Menée in vitro et in vivo, cette étude compare l'efficacité d'un nouveau composé anti-androgénique appelé Compound 30 avec celle du MVD3100 pour le traitement d'un cancer de la prostate résistant à la castration

A novel anti-androgen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo

Kuruma, Hidetoshi ; Matsumoto, Hiroaki ; Shiota, Masaki ; Bishop, Jennifer L. ; Lamoureux, Francois ; Thomas, Christian ; Briere, David ; Los, Gerrit ; Gleave, Martin ; Fanjul, Andrea ; Zoubeidi, Amina

Resistance to anti-androgen drugs, like MDV3100, occurs in patients with castration resistant prostate cancer (CRPC). Thus, preventing or treating anti-androgen resistance is a major clinical challenge. We identified a novel anti-androgen, Compound 30, and compared its efficacy to MDV3100. We found that Compound 30 inhibits AR activity in LNCaP cells, C4-2 cells, as well as MDV3100 resistant cell lines. Compared to MDV3100, Compound 30 treatment induces greater reduction in AR, PSA, and AR [...]

Menée à l'aide d'un modèle murin, cette étude évalue les effets d'un composé appelé TFD100, un glycopeptide purifié de morue se liant à la galectine 3 avec une affinité de l'ordre du picomolaire, sur le processus métastatique d'un adénocarcinome de la prostate

Cod glycopeptide with picomolar affinity to galectin-3 suppresses T-cell apoptosis and prostate cancer metastasis

Guha, Prasun ; Kaptan, Engin ; Bandyopadhyaya, Gargi ; Kaczanowska, Sabina ; Davila, Eduardo ; Thompson, Keyata ; Martin, Stuart S. ; Kalvakolanu, Dhananjaya V. ; Vasta, Gerardo R. ; Ahmed, Hafiz

Cancer metastasis and immune suppression are critical issues in cancer therapy. Here, we show that a β-galactoside–binding lectin [galectin-3 (gal3)] that recognizes the Thomsen-Friedenreich disaccharide (TFD, Galβ1,3GalNAc) present on the surface of most cancer cells is involved in promoting angiogenesis, tumor-endothelial cell adhesion, and metastasis of prostate cancer cells, as well as evading immune surveillance through killing of activated T cells. To block gal3-mediated interactions, we [...]

A partir de données portant sur un total de 6 486 patients atteints de divers types de tumeurs solides et inclus dans 7 essais de phase III évaluant le bevacizumab, cette étude évalue l'association entre une hypertension observée dans les deux premiers mois de traitement et la réponse thérapeutique

Analysis of Early Hypertension and Clinical Outcome With Bevacizumab: Results From Seven Phase III Studies

Hurwitz, Herbert I. ; Douglas, Pamela S. ; Middleton, John P. ; Sledge, George W. ; Johnson, David H. ; Reardon, David A. ; Chen, Dafeng ; Rosen, Oliver

Background. Hypertension is associated with antivascular endothelial growth factor treatment, but the clinical implications of hypertension are uncertain. To assess the prognostic and predictive value of bevacizumab-related hypertension, a comprehensive analysis of whether hypertension and efficacy outcomes are associated was conducted on seven company-sponsored placebo-controlled phase III studies of bevacizumab. Methods. Patient-specific data were available from 6,486 patients with metastatic [...]

A partir de données portant sur des patients atteints d'une leucémie myéloïde chronique et inclus dans l'essai de phase III ENESTnd, cette étude analyse l'apparition de mutations du gène BCR-ABL associées à un traitement par imatinib ou nilotinib

Nilotinib is associated with a reduced incidence of BCR-ABL mutations versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase

Hochhaus, Andreas ; Saglio, Giuseppe ; Larson, Richard A. ; Kim, Dong-Wook ; Etienne, Gabriel ; Rosti, Gianantonio ; De Souza, Carmino ; Kurokawa, Mineo ; Kalaycio, Matt E. ; Hoenekopp, Albert ; Fan, Xiaolin ; Shou, Yaping ; Kantarjian, Hagop M. ; Hughes, Timothy P.

In patients with chronic myeloid leukemia, BCR-ABL mutations contribute to resistance to tyrosine kinase inhibitor therapy. We examined the occurrence of treatment-emergent mutations and their impact on response in patients from the ENESTnd phase 3 trial. At the 3-year data cutoff, mutations were detected in approximately twice as many patients on imatinib 400 mg once daily (21 patients) than on nilotinib (11 patients each on nilotinib 300 mg twice daily and nilotinib 400 mg twice daily). The [...]

Mené sur 224 patients atteints d'un lymphome diffus à grandes cellules B récidivant, cet essai de phase III compare, du point de vue de la survie sans progression à 2 ans, le tositumomab et le rituximab en complément d'une chimiothérapie à base de carmustine, étoposide, cytarabine et melphalan

Phase III Randomized Study of Rituximab/Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Compared With Iodine-131 Tositumomab/BEAM With Autologous Hematopoietic Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma: Results From the BMT CTN 0401 Trial

Vose, Julie M. ; Carter, Shelly ; Burns, Linda J. ; Ayala, Ernesto ; Press, Oliver W. ; Moskowitz, Craig H. ; Stadtmauer, Edward A. ; Mineshi, Shin ; Ambinder, Richard ; Fenske, Timothy ; Horowitz, Mary ; Fisher, Richard ; Tomblyn, Marcie

Purpose This clinical trial evaluated standard-dose radioimmunotherapy with a chemotherapy-based transplantation regimen followed by autologous hematopoietic cell transplantation versus rituximab with the same regimen in patients with relapsed diffuse large B-cell lymphoma (DLBCL). Patients and Methods Patients with chemotherapy-sensitive persistent or relapsed DLBCL were randomly assigned to receive iodine-131 tositumomab (dosimetric dose of 5 mCi on day −19 and therapeutic dose of 0.75 Gy on [...]

Menée sur 28 patients atteints d'un mélanome métastatique présentant la mutation V600E du gène BRAF, cette étude analyse les réactions cutanées indésirables associées au vemurafenib

RASopathic Skin Eruptions during Vemurafenib Therapy

Rinderknecht, Jeannine D. ; Goldinger, Simone M. ; Rozati, Sima ; Kamarashev, Jivko ; Kerl, Katrin ; French, Lars E. ; Dummer, Reinhard ; Belloni, Benedetta

Purpose : Vemurafenib is a potent inhibitor of V600 mutant BRAF with significant impact on progression-free and overall survival in advanced melanoma. Cutaneous side effects are frequent. This single-center observational study investigates clinical and histological features of these class-specific cutaneous adverse reactions. Patients and Methods : Patients were all treated with Vemurafenib 960 mg b.i.d. within local ethic committees approved clinical trials. All skin reactions were collected [...]

Menée sur 357 patients atteints d'un myélome multiple (durée médiane de suivi : 96 mois), cette étude évalue les résultats à long terme d'un essai comparant une allogreffe à conditionnement atténué, précédée d’une autogreffe de réduction tumorale, et une autogreffe seule

Autologous/reduced-intensity allogeneic stem cell transplantation versus autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study

Gahrton, Gösta ; Iacobelli, Simona ; Björkstrand, Bo ; Hegenbart, Ute ; Gruber, Astrid ; Greinix, Hildegard ; Volin, Liisa ; Narni, Franco ; Carella, Angelo Michele ; Beksac, Meral ; Bosi, Alberto ; Milone, Giuseppe ; Corradini, Paolo ; Schönland, Stefan ; Friberg, Kristina ; van Biezen, Anja ; Goldschmidt, Hartmut ; de Witte, Theo ; Morris, Curly ; Niederwieser, Dietger ; Garderet, Laurent ; Kröger, Nicolaus

Long-term follow up of prospective studies comparing allogeneic transplantation to autologous transplantation in multiple myeloma are few and controversial. This is an update at a median follow up of 96 months of the EBMT NMAM2000 myeloma study that prospectively compares tandem autologous/reduced intensity conditioning allogeneic transplantation (auto/RICallo) to autologous transplantation alone (auto). 357 myeloma patients up to the age of 69 years were enrolled. Patients with an [...]

Mené sur 37 patients atteints d'un cancer métastatique de la jonction œsophago-gastrique, cet essai de phase II évalue, du point de vue de la survie sans progression, un traitement combinant bevacizumab, oxaliplatine et capécitabine

A Phase II Study of Capecitabine, Oxaliplatin, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas

Uronis, Hope E. ; Bendell, Johanna C. ; Altomare, Ivy ; Blobe, Gerard C. ; Hsu, S. David ; Morse, Michael A. ; Pang, Herbert ; Zafar, S. Yousuf ; Conkling, Paul ; Favaro, Justin ; Arrowood, Christy C. ; Cushman, Stephanie M. ; Meadows, Kellen L. ; Brady, John C. ; Nixon, Andrew B. ; Hurwitz, Herbert I.

Background. Esophageal and gastric cancers often present at an advanced stage. Systemic chemotherapy is the mainstay of treatment, but survival with current regimens remains poor. We evaluated the safety, tolerability, and efficacy of the combination capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas. Methods.Thirty-seven patients with metastatic or unresectable gastric/gastroesophageal junction tumors were enrolled and treated with [...]

Mené sur 888 patients atteintes d'un cancer de l'ovaire, cet essai de phase III évalue, du point de vue de la survie sans récidive, l'abagovomab après une opération chirurgicale et une chimiothérapie à base de taxanes et de sels de platine

Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICO—The MIMOSA Study

Sabbatini, Paul ; Harter, Philipp ; Scambia, Giovanni ; Sehouli, Jalid ; Meier, Werner ; Wimberger, Pauline ; Baumann, Klaus H. ; Kurzeder, Christian ; Schmalfeldt, Barbara ; Cibula, David ; Bidzinski, Mariusz ; Casado, Antonio ; Martoni, Andrea ; Colombo, Nicoletta ; Holloway, Robert W. ; Selvaggi, Luigi ; Li, Andrew ; del Campo, Jose ; Cwiertka, Karel ; Pintér, Tamás ; Vermorken, Jan B. ; Pujade-Lauraine, Eric ; Scartoni, Simona ; Bertolotti, Monica ; Simonelli, Cecilia ; Capriati, Angela ; Maggi, Carlo Alberto ; Berek, Jonathan S. ; Pfisterer, Jacobus

Purpose To determine whether abagovomab maintenance therapy prolongs recurrence-free (RFS) and overall survival (OS) in patients with ovarian cancer in first clinical remission. Patients and Methods Patients with International Federation of Gynecology and Obstetrics stage III to IV ovarian cancer in complete clinical remission after primary surgery and platinum- and taxane-based chemotherapy were randomly assigned at a ratio of 2:1 in a phase III, double-blind, placebo-controlled, multicenter [...]

A partir de données portant sur 42 patients atteints d'un cancer du poumon non à petites cellules et inclus dans deux essais d'évaluation du crizotinib, cette étude rétrospective analyse les caractéristiques cliniques associées à l'observation d'une bradycardie sinusale

Heart rate decrease during crizotinib treatment and potential correlation to clinical response

Ou, Sai-Hong Ignatius ; Tong, Wilson P. ; Azada, Michele ; Siwak-Tapp, Christina ; Dy, Joni ; Stiber, Jonathan A.

BACKGROUND: Crizotinib is used for the treatment of advanced anaplastic lymphoma kinase (ALK)-rearranged nonsmall cell lung cancer (NSCLC). Sinus bradycardia (SB) is a side effect listed in its package insert. We investigated the frequency and timing of SB, patient characteristics associated with SB during crizotinib treatment, and potential correlation between heart rate (HR) changes and clinical response to crizotinib. METHODS: A retrospective chart review was conducted of the timing and [...]

Mené sur 9 patients atteints d'un cancer des voies biliaires de stade avancé et réfractaire aux traitements de référence, cet essai de phase I évalue, du point de vue de la réponse tumorale, de la survie sans progression et de la survie globale, un vaccin à base de quatre peptides

Long-term vaccination with multiple peptides derived from cancer-testis antigens can maintain a specific T-cell response and achieve disease stability in advanced biliary tract cancer

Aruga, Atsushi ; Takeshita, Nobuhiro ; Kotera, Yoshihito ; OKUYAMA, RYUJI ; Matsushita, Norimasa ; Ohta, Takehiro ; Takeda, Kazuyoshi ; Yamamoto, Masakazu

Purpose: The prognosis of patients with advanced biliary tract cancer is extremely poor and there are only a few standard treatments. We performed a phase I trial to investigate the safety, immune response and anti-tumor effect of vaccination with four peptides derived from cancer-testis antigens, with a focus on their fluctuations during long-term vaccination until the disease had progressed. Experimental Design: Nine patients with advanced biliary tract cancer who had unresectable tumors and [...]

Menée sur 239 patients attteints d'un cancer du poumon non à petites cellules de stade II, IIIA ou IIIB (âge : 34 à 78 ans), cette étude évalue, du point de vue du taux de réponse complète pathologique et par rapport à une radiothérapie avec fractionnement conventionnel, l'intérêt d'une radiothérapie hyperfractionnée accélérée dans le cadre d'un traitement trimodal comportant une chimiothérapie d'induction suivie d'une chimioradiothérapie

Accelerated hyperfractionated radiotherapy within trimodality therapy concepts for stage IIIA/B non-small cell lung cancer: Markedly higher rate of pathologic complete remissions than with conventional fractionation

Pöttgen, C. ; Eberhardt, W. ; Graupner, B. ; Theegarten, D. ; Gauler, T. ; Freitag, L. ; Abu Jawad, J. ; Wohlschlaeger, J. ; Welter, S. ; Stamatis, G. ; Stuschke, M.

Background Radiation dose escalation within definitive radiochemotherapy (RTx/CTx) was not successful for stage III non-small cell lung cancer (NSCLC) using conventional fractionation (CF). Accelerated-hyperfractionation (AHF) counteracts tumour cell repopulation. In this observational study, the effects of neoadjuvant RTx/CTx using AHF or CF were studied by histopathology and using the survival end-point. Methods Data from all consecutive lung cancer patients treated with neoadjuvant RTx/CTx [...]

Mené sur 49 patients atteints d'un cancer du poumon non à petites cellules, de stade III-A ou III-B et non résécable (âge médian : 63,4 ans ; 73,5 % d'hommes et 26,5 % de femmes), cet essai multicentrique de phase II évalue l'efficacité, du point de vue du taux de réponse et de la survie globale, et la tolérabilité d'une chimiothérapie d'induction par cisplatine–gemcitabine suivie par une chimioradiothérapie concomitante par cisplatine–gemcitabine

A phase II single-arm study of induction chemotherapy with cisplatin and gemcitabine followed by concurrent cisplatin and gemcitabine with thoracic radiation for unresectable locally advanced non-small cell lung cancer

Driesen, Peter ; Lambrechts, Marc ; Kraaij, Kees ; Soldatenkova, Victoria ; Chouaki, Nadia ; Colinet, Benoit

Objectives : The aim of this study was to evaluate the efficacy and tolerability of the combination of cisplatin–gemcitabine with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer (LA-NSCLC).Methods: This was a phase II, multicenter, open-label, single-arm trial in treatment-naïve patients with stage IIIA and IIIB LA-NSCLC. After three induction cycles with gemcitabine 1250 mg/m2 plus cisplatin 80 mg/m2, two concurrent chemoradiotherapy cycles with gemcitabine 300 [...]

A partir d'une revue systématique de la littérature publiée jusqu'en août 2012 (13 études), cette méta-analyse évalue l'intérêt des statines pour réduire le risque de récidive chez les patients atteints d'un cancer localisé de la prostate traité par prostatectomie radicale ou radiothérapie

Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis

Park, H. S. ; Schoenfeld, J. D. ; Mailhot, R. B. ; Shive, M. ; Hartman, R. I. ; Ogembo, R. ; Mucci, L. A.

Background In this meta-analysis, we evaluated associations between statins and recurrence-free survival (RFS) following treatment of localized prostate cancer, with attention to potential benefits among patients treated primarily with radiotherapy (RT) versus radical prostatectomy.Patients and methods We identified original studies examining the effect of statins on men who received definitive treatment of localized prostate cancer using a systematic search of the PubMed and EMBASE databases [...]

Cette étude décrit les caractéristiques des 447 essais cliniques de traitements du cancer du poumon non à petites cellules enregistrés dans la base clinicaltrials.gov en 2012 et analyse leur évolution depuis 2009

Review of Ongoing Clinical Trials in Non-Small-Cell Lung Cancer: A Status Report for 2012 from the ClinicalTrials.gov Web Site

Subramanian, Janakiraman ; Regenbogen, Thomas ; Nagaraj, Gayathri ; Lane, Alex ; Devarakonda, Siddhartha ; Zhou, Gongfu ; Govindan, Ramaswamy

Introduction: Clinical research in non-small-cell lung cancer (NSCLC) is a rapidly evolving field. In an effort to identify the current trends in lung cancer clinical research, we reviewed ongoing clinical trials in NSCLC listed in the ClinicalTrials.gov registry in 2012, and we also compared this data to a similar survey conducted by us in 2009. Methods: The Web site's advanced search function was used to search for the term "non-small cell lung cancer." The search was further refined by using [...]

A partir de données issues de 5 essais cliniques comparant une chimiothérapie à base de docétaxel avec une chimiothérapie à base de vinorelbine, cette méta-analyse évalue l'intérêt d'utiliser la survie sans progression comme critère de substitution à la survie globale dans les essais de traitements pour les patients atteints d'un cancer du poumon non à petites cellules de stade avancé

Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials

Laporte, Silvy ; Squifflet, Pierre ; Baroux, Noémie ; Fossella, Frank ; Georgoulias, Vassilis ; Pujol, Jean-Louis ; Douillard, Jean-Yves ; Kudoh, Shinzohy ; Pignon, Jean-Pierre ; Quinaux, Emmanuel ; Buyse, Marc

Objectives To investigate whether progression-free survival (PFS) can be considered a surrogate endpoint for overall survival (OS) in advanced non-small-cell lung cancer (NSCLC). Design Meta-analysis of individual patient data from randomised trials. Setting Five randomised controlled trials comparing docetaxel-based chemotherapy with vinorelbine-based chemotherapy for the first-line treatment of NSCLC. Participants 2331 patients with advanced NSCLC. Primary and secondary outcome measures [...]